Xinran Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Xinran Xu has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Jia Chen
Department of Environmental Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA
11 shared publications Alfred I. Neugut
Department of Epidemiology Columbia University New York NY USA
10 shared publicationsMarilie D. Gammon
Department of Epidemiology University of North Carolina at Chapel Hill Chapel Hill North Carolina USA
10 shared publicationsSusan L. Teitelbaum
Department of Preventive Medicine Mount Sinai School of Medicine New York NY USA
10 shared publicationsJames G. Wetmur
Department of Microbiology Mount Sinai School of Medicine New York NY USA
9 shared publicationsPatrick T. Bradshaw
Department of Epidemiology University of North Carolina at Chapel Hill Chapel Hill North Carolina USA
9 shared publications
Latest Publications
- 14 July 2022
- Published by Elsevier in Food Microbiology
- Vol. 108, 104092
Using E. coli population to predict foodborne pathogens in pastured poultry farms
- 14 July 2022
- Published by Elsevier in Food Microbiology
- Vol. 108, 104092
Using E. coli population to predict foodborne pathogens in pastured poultry farms
- Open Access
- 1 June 2021
- Published by Elsevier in Poultry Science
- Vol. 100 (6) , 101122
Using farm management practices to predict Campylobacter prevalence in pastured poultry farms
- 1 June 2021
- Published by Elsevier in Poultry Science
- Vol. 100 (6) , 101122
Open AccessUsing farm management practices to predict Campylobacter prevalence in pastured poultry farms
- Open Access
- 1 June 2014
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 18 (9) , 1830-1839
miRNA‐940 reduction contributes to human Tetralogy of Fallot development
Tetralogy of Fallot (TOF) is a complex congenital heart defect and the microRNAs regulation in TOF development is largely unknown. Herein, we explored the role of miRNAs in TOF. Among 75 dysregulated miRNAs identified from human heart tissues, miRNA‐940 was the most down‐regulated one. Interestingly, miRNA‐940 was most highly expressed in normal human right ventricular out‐flow tract comparing to other heart chambers. As TOF is caused by altered proliferation, migration and/or differentiation of the progenitor cells of the secondary heart field, we isolated Sca‐1+ human cardiomyocyte progenitor cells (hCMPC) for miRNA‐940 function analysis. miRNA‐940 reduction significantly promoted hCMPCs proliferation and inhibited hCMPCs migration. We found that JARID2 is an endogenous target regulated by miRNA‐940. Functional analyses showed that JARID2 also affected hCMPCs proliferation and migration. Thus, decreased miRNA‐940 affects the proliferation and migration of the progenitor cells of the secondary heart field by targeting JARID2 and potentially leads to TOF development.
- 1 June 2014
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 18 (9) , 1830-1839
Open AccessmiRNA‐940 reduction contributes to human Tetralogy of Fallot development
Tetralogy of Fallot (TOF) is a complex congenital heart defect and the microRNAs regulation in TOF development is largely unknown. Herein, we explored the role of miRNAs in TOF. Among 75 dysregulated miRNAs identified from human heart tissues, miRNA‐940 was the most down‐regulated one. Interestingly, miRNA‐940 was most highly expressed in normal human right ventricular out‐flow tract comparing to other heart chambers. As TOF is caused by altered proliferation, migration and/or differentiation of the progenitor cells of the secondary heart field, we isolated Sca‐1+ human cardiomyocyte progenitor cells (hCMPC) for miRNA‐940 function analysis. miRNA‐940 reduction significantly promoted hCMPCs proliferation and inhibited hCMPCs migration. We found that JARID2 is an endogenous target regulated by miRNA‐940. Functional analyses showed that JARID2 also affected hCMPCs proliferation and migration. Thus, decreased miRNA‐940 affects the proliferation and migration of the progenitor cells of the secondary heart field by targeting JARID2 and potentially leads to TOF development.
- 1 October 2012
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 427 (1) , 73-79
Prolyl hydroxylase domain protein 2 regulates the intracellular cyclic AMP level in cardiomyocytes through its interaction with phosphodiesterase 4D
- 1 October 2012
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 427 (1) , 73-79
Prolyl hydroxylase domain protein 2 regulates the intracellular cyclic AMP level in cardiomyocytes through its interaction with phosphodiesterase 4D
- Open Access
- 27 February 2012
- Published by Wiley in The FASEB Journal
- Vol. 26 (6) , 2657-2666
DNA methylation in peripheral blood measured by LUMA is associated with breast cancer in a population‐based study
Our purpose was to identify epigenetic markers of breast cancer risk, which can be reliably measured in peripheral blood and are amenable for large population screening. We used 2 independent assays, luminometric methylation assay (LUMA) and long interspersed elements‐1 (LINE‐1) to measure “global methylation content” in peripheral blood DNA from a well‐characterized population‐based case‐control study. We examined associations between methylation levels and breast cancer risk among 1055 cases and 1101 controls and potential influences of 1‐carbon metabolism on global methylation. Compared with women in the lowest quintile of LUMA methylation, those in the highest quintile had a 2.41‐fold increased risk of breast cancer (95% confidence interval: 1.83‐3.16; P , trend>0.0001). The association did not vary by other key tumor characteristics and lifestyle risk factors. Consistent with LUMA findings, genome‐wide methylation profiling of a subset of samples revealed greater promoter hypermethylation in breast cancer case participants ( P =0.04); higher LUMA was associated with higher promoter methylation in the controls ( P =0.05). LUMA levels were also associated with functional sodium nitroprusside in key 1‐carbon metabolizing genes, MTHFR C677T ( P =0.001) and MTRR A66G ( P =0.018). LINE‐1 methylation was associated with neither breast cancer risk nor 1‐carbon metabolism. Our results show that global promoter hypermethylation measured in peripheral blood was associated with breast cancer risk.—Xu, X., Gammon, M. D., Hernandez‐Vargas, H., Herceg, Z., Wetmur, J. G., Teitelbaum, S. L., Bradshaw, P. T., Neugut, A. I., Santella, R. M., Chen, J. DNA methylation in peripheral blood measured by LUMA is associated with breast cancer in a population‐based study. FASEB J. 26, 2657‐2666 (2012). www.fasebj.org
- 27 February 2012
- Published by Wiley in The FASEB Journal
- Vol. 26 (6) , 2657-2666
Open AccessDNA methylation in peripheral blood measured by LUMA is associated with breast cancer in a population‐based study
Our purpose was to identify epigenetic markers of breast cancer risk, which can be reliably measured in peripheral blood and are amenable for large population screening. We used 2 independent assays, luminometric methylation assay (LUMA) and long interspersed elements‐1 (LINE‐1) to measure “global methylation content” in peripheral blood DNA from a well‐characterized population‐based case‐control study. We examined associations between methylation levels and breast cancer risk among 1055 cases and 1101 controls and potential influences of 1‐carbon metabolism on global methylation. Compared with women in the lowest quintile of LUMA methylation, those in the highest quintile had a 2.41‐fold increased risk of breast cancer (95% confidence interval: 1.83‐3.16; P , trend>0.0001). The association did not vary by other key tumor characteristics and lifestyle risk factors. Consistent with LUMA findings, genome‐wide methylation profiling of a subset of samples revealed greater promoter hypermethylation in breast cancer case participants ( P =0.04); higher LUMA was associated with higher promoter methylation in the controls ( P =0.05). LUMA levels were also associated with functional sodium nitroprusside in key 1‐carbon metabolizing genes, MTHFR C677T ( P =0.001) and MTRR A66G ( P =0.018). LINE‐1 methylation was associated with neither breast cancer risk nor 1‐carbon metabolism. Our results show that global promoter hypermethylation measured in peripheral blood was associated with breast cancer risk.—Xu, X., Gammon, M. D., Hernandez‐Vargas, H., Herceg, Z., Wetmur, J. G., Teitelbaum, S. L., Bradshaw, P. T., Neugut, A. I., Santella, R. M., Chen, J. DNA methylation in peripheral blood measured by LUMA is associated with breast cancer in a population‐based study. FASEB J. 26, 2657‐2666 (2012). www.fasebj.org
- 1 November 2011
- Published by Taylor & Francis in Epigenetics
- Vol. 6 (11) , 1276-1283
The influence of one-carbon metabolism on gene promoter methylation in a population-based breast cancer study
Abnormal methylation in gene promoters is a hallmark of the cancer genome; however, factors that may influence promoter methylation have not been well elucidated. As the one-carbon metabolism pathw...
- 1 November 2011
- Published by Taylor & Francis in Epigenetics
- Vol. 6 (11) , 1276-1283
The influence of one-carbon metabolism on gene promoter methylation in a population-based breast cancer study
Abnormal methylation in gene promoters is a hallmark of the cancer genome; however, factors that may influence promoter methylation have not been well elucidated. As the one-carbon metabolism pathw...
- 12 August 2011
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 131 (1) , 197-205
Prognostic significance of gene-specific promoter hypermethylation in breast cancer patients
The association between promoter methylation status and survival was investigated in a large cohort of women with breast cancer, participants in the Long Island Breast Cancer Study Project. Archived tumor tissues (n = 839) were collected from women diagnosed with a first primary invasive or in situ breast cancer in 1996–1997. Vital status was followed through the end of 2005 with a mean follow-up time of 8 years. Promoter methylation of eight breast cancer-related genes was assessed by MethyLight. The frequencies of methylation for HIN1, RASSF1A, DAPK1, GSTP1, CyclinD2, TWIST, CDH1 and RARβ were 62.9, 85.2, 14.1, 27.8, 19.6, 15.3, 5.8 and 27.6%, respectively. Since survival rates of in situ and invasive breast cancers are substantially different, survival analyses were conducted within 670 invasive cases with complete data on all genes. Age-adjusted Cox proportional hazards models revealed that GSTP1, TWIST and RARβ methylation was significantly associated with higher breast cancer-specific mortality. Methylation of GSTP1 and RARβ was significantly associated with higher all-cause mortality. To investigate the relationship between the number of methylated genes and breast cancer-specific mortality, we included previously published MethyLight data on p16 and APC methylation status. Breast cancer-specific mortality increased in a dose-dependent manner with increasing number of methylated genes (P trend = 0.002), although confidence intervals were wide. Our results suggest that promoter methylation, particularly for a panel of genes, has the potential to be used as a biomarker for predicting prognosis in breast cancer.
- 12 August 2011
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 131 (1) , 197-205
Prognostic significance of gene-specific promoter hypermethylation in breast cancer patients
The association between promoter methylation status and survival was investigated in a large cohort of women with breast cancer, participants in the Long Island Breast Cancer Study Project. Archived tumor tissues (n = 839) were collected from women diagnosed with a first primary invasive or in situ breast cancer in 1996–1997. Vital status was followed through the end of 2005 with a mean follow-up time of 8 years. Promoter methylation of eight breast cancer-related genes was assessed by MethyLight. The frequencies of methylation for HIN1, RASSF1A, DAPK1, GSTP1, CyclinD2, TWIST, CDH1 and RARβ were 62.9, 85.2, 14.1, 27.8, 19.6, 15.3, 5.8 and 27.6%, respectively. Since survival rates of in situ and invasive breast cancers are substantially different, survival analyses were conducted within 670 invasive cases with complete data on all genes. Age-adjusted Cox proportional hazards models revealed that GSTP1, TWIST and RARβ methylation was significantly associated with higher breast cancer-specific mortality. Methylation of GSTP1 and RARβ was significantly associated with higher all-cause mortality. To investigate the relationship between the number of methylated genes and breast cancer-specific mortality, we included previously published MethyLight data on p16 and APC methylation status. Breast cancer-specific mortality increased in a dose-dependent manner with increasing number of methylated genes (P trend = 0.002), although confidence intervals were wide. Our results suggest that promoter methylation, particularly for a panel of genes, has the potential to be used as a biomarker for predicting prognosis in breast cancer.
- 1 July 2010
- Published by Elsevier in Toxicology Letters
- Vol. 196, S47
Global DNA methylation and risk of breast cancer in Mexican women
- 1 July 2010
- Published by Elsevier in Toxicology Letters
- Vol. 196, S47
Global DNA methylation and risk of breast cancer in Mexican women
- 15 April 2010
- Published by American Association for Cancer Research (AACR)
- Vol. 70 (8) , 4942
Abstract 4942: The role of one-carbon metabolism in global and promoter methylation of breast cancer in a population-based study
- 15 April 2010
- Published by American Association for Cancer Research (AACR)
- Vol. 70 (8) , 4942
Abstract 4942: The role of one-carbon metabolism in global and promoter methylation of breast cancer in a population-based study